Global Biosimilar and Interchangeable Biologics Market Growth (Status and Outlook) 2024-2030

Publication ID:

LPI07243731

Publication Date:

July 9, 2024

Pages:

127

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

A biosimilar (also known as follow-on biologic or subsequent entry biologic) is a biologic medical product that is almost an identical copy of an original product that manufactured by a different company. Biosimilar are officially approved versions of original "innovator" products and can manufactured when the original product's patent expires. Reference to the innovator product is an integral component of the approval. An interchangeable biosimilar is a biosimilar that meets additional requirements outlined by the law that allows for the FDA to approve biosimilar and interchangeable biosimilar medications. An interchangeable biosimilar product may be substituted for the original product without consulting the prescriber, much like how generic drugs are routinely substituted for brand name drugs.
The global Biosimilar and Interchangeable Biologics market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.
The 鈥淏iosimilar and Interchangeable Biologics Industry Forecast鈥� looks at past sales and reviews total world Biosimilar and Interchangeable Biologics sales in 2022, providing a comprehensive analysis by region and market sector of projected Biosimilar and Interchangeable Biologics sales for 2023 through 2029. With Biosimilar and Interchangeable Biologics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Biosimilar and Interchangeable Biologics industry.
This Insight Report provides a comprehensive analysis of the global Biosimilar and Interchangeable Biologics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Biosimilar and Interchangeable Biologics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Biosimilar and Interchangeable Biologics market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Biosimilar and Interchangeable Biologics and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Biosimilar and Interchangeable Biologics.
United States market for Biosimilar and Interchangeable Biologics is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Biosimilar and Interchangeable Biologics is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Biosimilar and Interchangeable Biologics is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Biosimilar and Interchangeable Biologics players cover Roche, Amgen, AbbVie, Sanofi, Johnson & Johnson, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Biosimilar and Interchangeable Biologics market by product type, application, key players and key regions and countries.
Segmentation by Type:
Monoclonal Antibodies
Interferon
Insulin
Vaccines
Others
Segmentation by Application:
Hospital
Retail Pharmacy
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
Segmentation by Type:
Monoclonal Antibodies
Interferon
Insulin
Vaccines
Others
Segmentation by Application:
Hospital
Retail Pharmacy
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Roche
Amgen
AbbVie
Sanofi
Johnson & Johnson
Pfizer
Novo Nordisk
Eli Lilly
Novartis
Merck
Biogen
Celltrion
Sobi
3SBIO
Changchun High Tech
Kanghong Pharma
Innovent Biologics
Gan&Lee
Tonghua Dongbao
United Laboratory

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Biosimilar and Interchangeable Biologics Market Size 2019-2030
2.1.2 Biosimilar and Interchangeable Biologics Market Size CAGR by Region (2019 VS 2023 VS 2030)
2.1.3 World Current & Future Analysis for Biosimilar and Interchangeable Biologics by Country/Region, 2019, 2023 & 2030
2.2 Biosimilar and Interchangeable Biologics Segment by Type
2.2.1 Monoclonal Antibodies
2.2.2 Interferon
2.2.3 Insulin
2.2.4 Vaccines
2.2.5 Others
2.3 Biosimilar and Interchangeable Biologics Market Size by Type
2.3.1 Biosimilar and Interchangeable Biologics Market Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Biosimilar and Interchangeable Biologics Market Size Market Share by Type (2019-2024)
2.4 Biosimilar and Interchangeable Biologics Segment by Application
2.4.1 Hospital
2.4.2 Retail Pharmacy
2.4.3 Other
2.5 Biosimilar and Interchangeable Biologics Market Size by Application
2.5.1 Biosimilar and Interchangeable Biologics Market Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Biosimilar and Interchangeable Biologics Market Size Market Share by Application (2019-2024)
3 Biosimilar and Interchangeable Biologics Market Size by Player
3.1 Biosimilar and Interchangeable Biologics Market Size Market Share by Player
3.1.1 Global Biosimilar and Interchangeable Biologics Revenue by Player (2019-2024)
3.1.2 Global Biosimilar and Interchangeable Biologics Revenue Market Share by Player (2019-2024)
3.2 Global Biosimilar and Interchangeable Biologics Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Biosimilar and Interchangeable Biologics by Region
4.1 Biosimilar and Interchangeable Biologics Market Size by Region (2019-2024)
4.2 Global Biosimilar and Interchangeable Biologics Annual Revenue by Country/Region (2019-2024)
4.3 Americas Biosimilar and Interchangeable Biologics Market Size Growth (2019-2024)
4.4 APAC Biosimilar and Interchangeable Biologics Market Size Growth (2019-2024)
4.5 Europe Biosimilar and Interchangeable Biologics Market Size Growth (2019-2024)
4.6 Middle East & Africa Biosimilar and Interchangeable Biologics Market Size Growth (2019-2024)
5 Americas
5.1 Americas Biosimilar and Interchangeable Biologics Market Size by Country (2019-2024)
5.2 Americas Biosimilar and Interchangeable Biologics Market Size by Type (2019-2024)
5.3 Americas Biosimilar and Interchangeable Biologics Market Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Biosimilar and Interchangeable Biologics Market Size by Region (2019-2024)
6.2 APAC Biosimilar and Interchangeable Biologics Market Size by Type (2019-2024)
6.3 APAC Biosimilar and Interchangeable Biologics Market Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Biosimilar and Interchangeable Biologics Market Size by Country (2019-2024)
7.2 Europe Biosimilar and Interchangeable Biologics Market Size by Type (2019-2024)
7.3 Europe Biosimilar and Interchangeable Biologics Market Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Biosimilar and Interchangeable Biologics by Region (2019-2024)
8.2 Middle East & Africa Biosimilar and Interchangeable Biologics Market Size by Type (2019-2024)
8.3 Middle East & Africa Biosimilar and Interchangeable Biologics Market Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Biosimilar and Interchangeable Biologics Market Forecast
10.1 Global Biosimilar and Interchangeable Biologics Forecast by Region (2025-2030)
10.1.1 Global Biosimilar and Interchangeable Biologics Forecast by Region (2025-2030)
10.1.2 Americas Biosimilar and Interchangeable Biologics Forecast
10.1.3 APAC Biosimilar and Interchangeable Biologics Forecast
10.1.4 Europe Biosimilar and Interchangeable Biologics Forecast
10.1.5 Middle East & Africa Biosimilar and Interchangeable Biologics Forecast
10.2 Americas Biosimilar and Interchangeable Biologics Forecast by Country (2025-2030)
10.2.1 United States Market Biosimilar and Interchangeable Biologics Forecast
10.2.2 Canada Market Biosimilar and Interchangeable Biologics Forecast
10.2.3 Mexico Market Biosimilar and Interchangeable Biologics Forecast
10.2.4 Brazil Market Biosimilar and Interchangeable Biologics Forecast
10.3 APAC Biosimilar and Interchangeable Biologics Forecast by Region (2025-2030)
10.3.1 China Biosimilar and Interchangeable Biologics Market Forecast
10.3.2 Japan Market Biosimilar and Interchangeable Biologics Forecast
10.3.3 Korea Market Biosimilar and Interchangeable Biologics Forecast
10.3.4 Southeast Asia Market Biosimilar and Interchangeable Biologics Forecast
10.3.5 India Market Biosimilar and Interchangeable Biologics Forecast
10.3.6 Australia Market Biosimilar and Interchangeable Biologics Forecast
10.4 Europe Biosimilar and Interchangeable Biologics Forecast by Country (2025-2030)
10.4.1 Germany Market Biosimilar and Interchangeable Biologics Forecast
10.4.2 France Market Biosimilar and Interchangeable Biologics Forecast
10.4.3 UK Market Biosimilar and Interchangeable Biologics Forecast
10.4.4 Italy Market Biosimilar and Interchangeable Biologics Forecast
10.4.5 Russia Market Biosimilar and Interchangeable Biologics Forecast
10.5 Middle East & Africa Biosimilar and Interchangeable Biologics Forecast by Region (2025-2030)
10.5.1 Egypt Market Biosimilar and Interchangeable Biologics Forecast
10.5.2 South Africa Market Biosimilar and Interchangeable Biologics Forecast
10.5.3 Israel Market Biosimilar and Interchangeable Biologics Forecast
10.5.4 Turkey Market Biosimilar and Interchangeable Biologics Forecast
10.6 Global Biosimilar and Interchangeable Biologics Forecast by Type (2025-2030)
10.7 Global Biosimilar and Interchangeable Biologics Forecast by Application (2025-2030)
10.7.1 GCC Countries Market Biosimilar and Interchangeable Biologics Forecast
11 Key Players Analysis
11.1 Roche
11.1.1 Roche Company Information
11.1.2 Roche Biosimilar and Interchangeable Biologics Product Offered
11.1.3 Roche Biosimilar and Interchangeable Biologics Revenue, Gross Margin and Market Share (2019-2024)
11.1.4 Roche Main Business Overview
11.1.5 Roche Latest Developments
11.2 Amgen
11.2.1 Amgen Company Information
11.2.2 Amgen Biosimilar and Interchangeable Biologics Product Offered
11.2.3 Amgen Biosimilar and Interchangeable Biologics Revenue, Gross Margin and Market Share (2019-2024)
11.2.4 Amgen Main Business Overview
11.2.5 Amgen Latest Developments
11.3 AbbVie
11.3.1 AbbVie Company Information
11.3.2 AbbVie Biosimilar and Interchangeable Biologics Product Offered
11.3.3 AbbVie Biosimilar and Interchangeable Biologics Revenue, Gross Margin and Market Share (2019-2024)
11.3.4 AbbVie Main Business Overview
11.3.5 AbbVie Latest Developments
11.4 Sanofi
11.4.1 Sanofi Company Information
11.4.2 Sanofi Biosimilar and Interchangeable Biologics Product Offered
11.4.3 Sanofi Biosimilar and Interchangeable Biologics Revenue, Gross Margin and Market Share (2019-2024)
11.4.4 Sanofi Main Business Overview
11.4.5 Sanofi Latest Developments
11.5 Johnson & Johnson
11.5.1 Johnson & Johnson Company Information
11.5.2 Johnson & Johnson Biosimilar and Interchangeable Biologics Product Offered
11.5.3 Johnson & Johnson Biosimilar and Interchangeable Biologics Revenue, Gross Margin and Market Share (2019-2024)
11.5.4 Johnson & Johnson Main Business Overview
11.5.5 Johnson & Johnson Latest Developments
11.6 Pfizer
11.6.1 Pfizer Company Information
11.6.2 Pfizer Biosimilar and Interchangeable Biologics Product Offered
11.6.3 Pfizer Biosimilar and Interchangeable Biologics Revenue, Gross Margin and Market Share (2019-2024)
11.6.4 Pfizer Main Business Overview
11.6.5 Pfizer Latest Developments
11.7 Novo Nordisk
11.7.1 Novo Nordisk Company Information
11.7.2 Novo Nordisk Biosimilar and Interchangeable Biologics Product Offered
11.7.3 Novo Nordisk Biosimilar and Interchangeable Biologics Revenue, Gross Margin and Market Share (2019-2024)
11.7.4 Novo Nordisk Main Business Overview
11.7.5 Novo Nordisk Latest Developments
11.8 Eli Lilly
11.8.1 Eli Lilly Company Information
11.8.2 Eli Lilly Biosimilar and Interchangeable Biologics Product Offered
11.8.3 Eli Lilly Biosimilar and Interchangeable Biologics Revenue, Gross Margin and Market Share (2019-2024)
11.8.4 Eli Lilly Main Business Overview
11.8.5 Eli Lilly Latest Developments
11.9 Novartis
11.9.1 Novartis Company Information
11.9.2 Novartis Biosimilar and Interchangeable Biologics Product Offered
11.9.3 Novartis Biosimilar and Interchangeable Biologics Revenue, Gross Margin and Market Share (2019-2024)
11.9.4 Novartis Main Business Overview
11.9.5 Novartis Latest Developments
11.10 Merck
11.10.1 Merck Company Information
11.10.2 Merck Biosimilar and Interchangeable Biologics Product Offered
11.10.3 Merck Biosimilar and Interchangeable Biologics Revenue, Gross Margin and Market Share (2019-2024)
11.10.4 Merck Main Business Overview
11.10.5 Merck Latest Developments
11.11 Biogen
11.11.1 Biogen Company Information
11.11.2 Biogen Biosimilar and Interchangeable Biologics Product Offered
11.11.3 Biogen Biosimilar and Interchangeable Biologics Revenue, Gross Margin and Market Share (2019-2024)
11.11.4 Biogen Main Business Overview
11.11.5 Biogen Latest Developments
11.12 Celltrion
11.12.1 Celltrion Company Information
11.12.2 Celltrion Biosimilar and Interchangeable Biologics Product Offered
11.12.3 Celltrion Biosimilar and Interchangeable Biologics Revenue, Gross Margin and Market Share (2019-2024)
11.12.4 Celltrion Main Business Overview
11.12.5 Celltrion Latest Developments
11.13 Sobi
11.13.1 Sobi Company Information
11.13.2 Sobi Biosimilar and Interchangeable Biologics Product Offered
11.13.3 Sobi Biosimilar and Interchangeable Biologics Revenue, Gross Margin and Market Share (2019-2024)
11.13.4 Sobi Main Business Overview
11.13.5 Sobi Latest Developments
11.14 3SBIO
11.14.1 3SBIO Company Information
11.14.2 3SBIO Biosimilar and Interchangeable Biologics Product Offered
11.14.3 3SBIO Biosimilar and Interchangeable Biologics Revenue, Gross Margin and Market Share (2019-2024)
11.14.4 3SBIO Main Business Overview
11.14.5 3SBIO Latest Developments
11.15 Changchun High Tech
11.15.1 Changchun High Tech Company Information
11.15.2 Changchun High Tech Biosimilar and Interchangeable Biologics Product Offered
11.15.3 Changchun High Tech Biosimilar and Interchangeable Biologics Revenue, Gross Margin and Market Share (2019-2024)
11.15.4 Changchun High Tech Main Business Overview
11.15.5 Changchun High Tech Latest Developments
11.16 Kanghong Pharma
11.16.1 Kanghong Pharma Company Information
11.16.2 Kanghong Pharma Biosimilar and Interchangeable Biologics Product Offered
11.16.3 Kanghong Pharma Biosimilar and Interchangeable Biologics Revenue, Gross Margin and Market Share (2019-2024)
11.16.4 Kanghong Pharma Main Business Overview
11.16.5 Kanghong Pharma Latest Developments
11.17 Innovent Biologics
11.17.1 Innovent Biologics Company Information
11.17.2 Innovent Biologics Biosimilar and Interchangeable Biologics Product Offered
11.17.3 Innovent Biologics Biosimilar and Interchangeable Biologics Revenue, Gross Margin and Market Share (2019-2024)
11.17.4 Innovent Biologics Main Business Overview
11.17.5 Innovent Biologics Latest Developments
11.18 Gan&Lee
11.18.1 Gan&Lee Company Information
11.18.2 Gan&Lee Biosimilar and Interchangeable Biologics Product Offered
11.18.3 Gan&Lee Biosimilar and Interchangeable Biologics Revenue, Gross Margin and Market Share (2019-2024)
11.18.4 Gan&Lee Main Business Overview
11.18.5 Gan&Lee Latest Developments
11.19 Tonghua Dongbao
11.19.1 Tonghua Dongbao Company Information
11.19.2 Tonghua Dongbao Biosimilar and Interchangeable Biologics Product Offered
11.19.3 Tonghua Dongbao Biosimilar and Interchangeable Biologics Revenue, Gross Margin and Market Share (2019-2024)
11.19.4 Tonghua Dongbao Main Business Overview
11.19.5 Tonghua Dongbao Latest Developments
11.20 United Laboratory
11.20.1 United Laboratory Company Information
11.20.2 United Laboratory Biosimilar and Interchangeable Biologics Product Offered
11.20.3 United Laboratory Biosimilar and Interchangeable Biologics Revenue, Gross Margin and Market Share (2019-2024)
11.20.4 United Laboratory Main Business Overview
11.20.5 United Laboratory Latest Developments
12 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂